Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arbaclofen Placarbil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 3/20 | 0.47 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 4/20 | 0.43 |
| ▸ | FNTB | P49356 | 4/20 | 0.43 |
| ▸ | PTGFR | P43088 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbaclofen Placarbil SCHEMBL2472988 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL638204 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL349961 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL3375708 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14692761 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14689524 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14689601 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL12130896 | 0.91 | MAPT (0.39) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL13101899 | 0.91 | MAPT (0.40) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL2230566 | 0.91 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228772-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2025-07-17 | — | — | US | claimed |
| EP-4536194-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | EsoCap AG (CH) | 2025-04-16 | — | — | EP | claimed |
| CN-119317428-A | Drug delivery system comprising reflux inhibitors for application to esophageal mucosa | 伊斯凯普公司 | 2025-01-14 | — | — | CN | claimed |
| WO-2023237426-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | claimed |
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | XENOPORT, INC. (US) | 2018-09-11 | — | — | US | claimed |
| EP-2250143-B1 | METHOD FOR THE ENZYMATIC KINETIC RESOLUTION OF ACYLOXYALKYL THIOCARBONATES USED FOR THE SYNTHESIS OF ACYLOXYALKYL CARBAMATES | XENOPORT INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-9265748-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2016-02-23 | — | — | US | claimed |
| US-20150313865-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | XENOPORT, INC. (US) | 2015-11-05 | — | — | US | claimed |
| US-9139517-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-20140066501-A1 | Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use | XENOPORT, INC. (US) | 2014-03-06 | — | — | US | claimed |
| EP-2117517-B1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT | XENOPORT INC (US) | 2011-06-01 | — | — | EP | claimed |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | XENOPORT, INC. (US) | 2010-10-07 | — | — | US | claimed |
| US-20100137442-A2 | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment | XENOPORT, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | claimed |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-04-01 | — | — | US | claimed |
| US-20090197958-A1 | Sustained Release Particulate Oral Dosage Forms of (R) Baclofen and Methods of Treatment | XENOPORT, INC. (US) | 2009-08-06 | — | — | US | claimed |
| US-20090192325-A1 | ENANTIOMERICALLY RESOLVING ACYLOXYALKYL THIOCARBONATES USED IN SYNTHESIZING ACYLOXYALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2009-07-30 | — | — | US | claimed |
| US-20090118365-A1 | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain | XENOPORT, INC (US) | 2009-05-07 | — | — | US | claimed |
| US-20090041806-A1 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | XENOPORT, INC. (US) | 2009-02-12 | — | — | US | claimed |
| US-20080206332-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT | WILSHIRE PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118365-A1 | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain | GABBR1, GABBR2, GABRB2 | GABBR2 2/4885GABBR1 1/4885LMNA 2460/4885 |
| US-20100137442-A2 | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment | GABBR2, GABBR1, GABRB2 | GABBR2 1/4885GABBR1 2/4885LMNA 3246/4885 |
| US-20080206332-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT | GABBR2, GABBR1, GABRB2 | GABBR2 1/4885GABBR1 2/4885LMNA 3498/4885 |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | CPS1, ASNS, NAAA | GABBR2 1092/4885GABBR1 961/4885LMNA 3051/4885 |
| US-20090041806-A1 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | GABBR2, GABBR1, GABRB2 | GABBR2 1/4885GABBR1 2/4885LMNA 4067/4885 |
| US-20150313865-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | GABRB3, GABRB1, GABBR1 | GABBR2 4/4885GABBR1 3/4885LMNA 3272/4885 |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | CPS1, SI, ASNS | GABBR2 1366/4885GABBR1 1477/4885LMNA 1222/4885 |
| US-20140066501-A1 | Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use | GABRB3, GABRB1, GABBR1 | GABBR2 4/4885GABBR1 3/4885LMNA 3212/4885 |
| US-20090197958-A1 | Sustained Release Particulate Oral Dosage Forms of (R) Baclofen and Methods of Treatment | GABBR2, GABBR1, GABRB2 | GABBR2 1/4885GABBR1 2/4885LMNA 3235/4885 |
| US-20250228772-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | HSPA5, MLNR, HRH2 | GABBR2 475/4885GABBR1 790/4885LMNA 1353/4885 |
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | GABRB2, GABRB3, GABBR2 | GABBR2 3/4885GABBR1 5/4885LMNA 4249/4885 |
| US-20090192325-A1 | ENANTIOMERICALLY RESOLVING ACYLOXYALKYL THIOCARBONATES USED IN SYNTHESIZING ACYLOXYALKYL CARBAMATE PRODRUGS | AADAC, NAAA, APEH | GABBR2 1464/4885GABBR1 1205/4885LMNA 4118/4885 |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | GABRB2, GABRB3, GABBR2 | GABBR2 3/4885GABBR1 5/4885LMNA 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.